Management of Acute Bronchitis in Immunocompetent Adults (Evidence‑Based Recommendations)

Recommendations Against Routine Pharmacologic Therapies

Do not prescribe routine inhalers (short‑acting beta‑agonists, anticholinergics, or inhaled corticosteroids) for outpatient adults with acute bronchitis because current evidence shows no benefit in reducing cough severity or duration. CHEST guideline (2020) – recommendation pending proof of safety/effectiveness. 7
Reassess patients whose symptoms persist or worsen for alternative diagnoses such as asthma, COPD exacerbation, pneumonia, or bronchiectasis. CHEST guideline (2020). 7
Retrospective data indicate that about two‑thirds of patients with recurrent “acute bronchitis” actually have mild asthma, highlighting the need for diagnostic reconsideration. CHEST guideline (2020). 7
Targeted investigations (chest radiograph, peak flow measurement, sputum culture) are recommended when the clinical picture is atypical or not improving. CHEST guideline (2020). 7

Short‑acting beta‑agonists are a first‑line inhaler to control bronchospasm, relieve dyspnea, and may reduce chronic cough. Grade A recommendation. CHEST guideline (2006). [8][9]10
Ipratropium bromide (anticholinergic) improves cough frequency and severity; also a Grade A first‑line option. CHEST guideline (2006). [8][9][10][11]
For patients with more severe disease, a long‑acting beta‑agonist combined with inhaled corticosteroid is recommended to control chronic cough. Grade A recommendation. CHEST guideline (2006). [8][10][12][13]
Inhaled corticosteroids are advised for patients whose FEV₁ is < 50 % predicted or who experience frequent exacerbations. CHEST guideline (2006). [8][14]

Initial therapy should start with either a short‑acting beta‑agonist or an anticholinergic bronchodilator. CHEST guideline (2006). [9][15]13
If the response is inadequate, add the alternative bronchodilator after maximizing the dose of the first agent. CHEST guideline (2006). [9][15]13
Theophylline should be avoided during acute exacerbations. Grade D recommendation. CHEST guideline (2006). [9][15]14

Common error: labeling recurrent episodes as “acute bronchitis” when the underlying condition is undiagnosed asthma or COPD. Clinicians should look for a pattern of similar episodes and a smoking history. CHEST guideline (2020). [7][8]
Antibiotics provide no meaningful benefit for uncomplicated acute bronchitis; they shorten cough by only ~0.5 day while exposing patients to adverse effects. Reserve antibiotics for suspected bacterial complications. CHEST guideline (2020). 7